On Demand Pharmaceuticals Welcomes HHS Leadership to Showcase Breakthrough Domestic Pharmaceutical Manufacturing Capabilities

ROCKVILLE, Md., Aug. 14, 2025 /PRNewswire/ -- Today, On Demand Pharmaceuticals (ODP) hosted senior officials from the U.S. Department of Health and Human Services (HHS) at its Centralized Production and Repackaging (CPR) facility in Rockville, Maryland. The visit also featured a live virtual demonstration of ODP's Pharmacy on Demand^® (PoD) platform in action, streaming directly from its Tupelo site at North Mississippi Medical Center. Attendees witnessed real-time formulation of an essential medicine – a powerful showcase of ODP's distributed Quality Management System and the agility of its point-of-care medicine production.

This visit marks a significant milestone in the multi-year collaboration between ODP, the Department of Defense (DoD), with the Office of Naval Research, and HHS's Administration for Strategic Preparedness and Response (ASPR), focused on reshoring America's pharmaceutical manufacturing infrastructure. As the U.S. continues to confront persistent drug shortages and supply chain disruptions, stemming predominantly from quality and reliability issues of foreign manufacturers, ODP's distributed manufacturing model offers a resilient, scalable, and rapid-response solution to deliver vital medications when and where they are needed.

"At ODP, we have reimagined pharmaceutical manufacturing using the most advanced techniques to ensure quality and provide transparency. We are positioned to scale delivery of our nation's most essential medications, made in America," said Matt Pietras, Chief Executive Officer of On Demand Pharmaceuticals. "Today's visit by HHS underscores our shared commitment to building a more transparent, secure and agile domestic pharmaceutical supply chain. Through our Pharmacy on Demand™ (PoD) platform combined with our API production and repackaging capabilities, ODP is delivering a first-of-its-kind solution to produce essential medicines at or near the point of care."

ODP's modular PoD can produce sterile medications at or near health systems, making it uniquely suited to address drug shortages, eliminate single points of failure caused by natural disasters, and address public health emergencies. The platform is powered by AI-driven process controls and integrates end-to-end production, from chemical synthesis to final formulation and packaging.

The CPR facility in Rockville serves as a key national resource for the domestic small-scale manufacturing of active pharmaceutical ingredients (APIs), long dominated by foreign suppliers. According to HHS, over 90% of generic sterile injectable APIs used in U.S. acute care hospitals rely on foreign sources, creating significant vulnerabilities.

Leveraging significant public and private funding to date, ODP is delivering on its bold mission to improve medication access, eliminate drug shortages and establish a novel platform for on-demand production of therapeutics at or near the point of care. The company is expanding its formulary to include medicines most at risk of shortage and is beginning to build its nationwide network of distributed production nodes to improve patient access, enhance national security, and reduce reliance on foreign supply chains.

ODP's model is focused on securing the supply chain for our nation's most essential medications and directly supports the HHS-led initiative to "make the United States the most competitive nation in the world for the manufacture of safe and effective pharmaceutical products."

About On Demand Pharmaceuticals

On Demand Pharmaceuticals (ODP) is revolutionizing the pharmaceutical supply chain with its Pharmacy on Demand^® technology, enabling on-site drug production to mitigate shortages and improve medication access. With a focus on advanced manufacturing, regulatory excellence, and supply chain resilience, ODP is redefining the future of pharmaceuticals.

For more information about On Demand Pharmaceuticals and its innovative solutions, visit www.ondemandpharma.com.

SOURCE On Demand Pharmaceuticals